Some bispecific antibodies are currently in clinical development, such as antibodies targeting HER2/HER3 [86,87] in breast, pancreatic and gastric cancer, EGFR/leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) in solid tumors, CD3/C-type lectin domain family 12 member A (CLEC12A) in acute myeloid leukemia [88], PD-L1/CD137 and EGFR/cMET in solid tumors. This evidence concerns the gene CLEC12A and gastric cancer.